AmunBio Team
Weidong Xu, PhD, Principal Scientist
Cecilia Zapata-Harms, MS, MHA Operations and Management
Cecilia Zapata-Harms, MS, MHA Operations and Management
Receiving his Ph.D in Department of Molecular Physiology and Biophysics, University of Iowa, Dr. Xu explored the cross-disciplinary field of translational medicine. Becoming an expert in cancer gene therapy while working with Dr. Seth. His work has increased therapeutic efficacy of oncolytic viruses. Currently he is a principal investigator at NorthShore University Health System, a teaching affiliate of University of Chicago.
Cecilia Zapata-Harms, MS, MHA Operations and Management
Cecilia Zapata-Harms, MS, MHA Operations and Management
Cecilia Zapata-Harms, MS, MHA Operations and Management
CEO of Palmetto InnovaSphere Institute with 30+ years experience in life science and cancer research operations and administration. Member of the founder team, Rosetta Inpharmatics; member of the strategic development founder team, Seattle Cancer Care Alliance; division administrator of molecular pharmacology at Fred Hutchinson Cancer Research Center and director of affiliate network, Seattle Cancer Care Alliance. Founder of Women, Life and Science Foundation
AmunBio Scientific Advisory Board
Andrei Shustov, MD
Nancy Whiting, PharmD
Nancy Whiting, PharmD
Expansive lead role in multiple cancer drug FDA approvals, expert in hematologic malignancies (non-hodgkins, hodgkins lymphomas, acute and chornic leukemias), focused on systemic and cutaneous T-cell lymphomas; pivotal member of the immunotherapy program at Fred Hutchinson Cancer Research Center; founder of T-cell leukemia lymphoma foundation. Currently, Sr. VP for Cellector BioSciences, Inc.
Nancy Whiting, PharmD
Nancy Whiting, PharmD
Nancy Whiting, PharmD
Seasoned executive and leader in drug development, Held an Executive VP and Corporate Strategy role for Seattle Genetics. Received her PharmD at the University of Washington, Sr. Oncology Medical Scientist for GSK. Named as top woman executive and leader in the life science industry. Nancy is currently CEO of Recludix Pharma
John Stewart, IV, MD, MBA
John Stewart, IV, MD, MBA
John Stewart, IV, MD, MBA
Dr. Stewart serves as the Surgeon in Chief for Morehouse School of Medicine and directs the clinical vision, mission, and strategies for the Morehouse School of Medicine’s department of surgery.
David T. Curiel, MD, PhD
John Stewart, IV, MD, MBA
John Stewart, IV, MD, MBA
Professor of Radiation Oncology and director of the Biologic Therapeutics Center at the School of Medicine, Washington University.